chronic hepatitis. Chronic persistent hepatitis
Conditions
Interventions
Intervention 1: In intervention group, Atorvastatin tablet, 20 mg, oral, once daily, for six months. Intervention 2: In control group, Atorvastatin placebo, oral, once daily, for six months.
Treatment - Drugs
Placebo
In intervention group, Atorvastatin tablet, 20 mg, oral, once daily, for six months
In control group, Atorvastatin placebo, oral, once daily, for six months
Sponsors
Qom University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients between 18 and 75 years old with chronic hepatitis B for more than 6 months and dysfunction in liver function, serum LDL more than 90 mg/dl Exclusion criteria: Patients with hepatitis B less than 6 months, Inactive carriers of hepatitis B, Patients with no fibrosis and cirrhosis, Patients with decompensated cirrhosis, Patients with chronic liver disease such as willson and hemochromatosis, Patients with hepatic cell carcinoma, Patients with other malignancies, Patients with co-infection and superinfection of HIV ,HCV or HDV, Patients that were treated with Atorvastatin, Pregnant and lactating women, Increasing of liver enzymes 2 times of normal range after 1 months of treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sevirity of fibrosis. Timepoint: Six months after begining intervention. Method of measurement: kpa with fibroscan.;Liver function. Timepoint: Six months after intervention. Method of measurement: Child score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver enzymes levels. Timepoint: Six month after begining of intervention. Method of measurement: Blood levels with IU/ml. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahdi Jahangiry
Qom University of Medical Sciences
Outcome results
None listed